| 1 | 1 | | 88R11662 LRM-F |
|---|
| 2 | 2 | | By: Raymond H.B. No. 4288 |
|---|
| 3 | 3 | | |
|---|
| 4 | 4 | | |
|---|
| 5 | 5 | | A BILL TO BE ENTITLED |
|---|
| 6 | 6 | | AN ACT |
|---|
| 7 | 7 | | relating to a study on the use of alternative therapies for treating |
|---|
| 8 | 8 | | post-traumatic stress disorder. |
|---|
| 9 | 9 | | BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS: |
|---|
| 10 | 10 | | SECTION 1. Sections 1(b), (c), (d), and (f), Chapter 983 |
|---|
| 11 | 11 | | (H.B. 1802), Acts of the 87th Legislature, Regular Session, 2021, |
|---|
| 12 | 12 | | are amended to read as follows: |
|---|
| 13 | 13 | | (b) The commission, in collaboration with Baylor College of |
|---|
| 14 | 14 | | Medicine and in partnership with a military veterans hospital, [or] |
|---|
| 15 | 15 | | a medical center that provides medical care to veterans, or a |
|---|
| 16 | 16 | | facility licensed in this state that provides Ketamine-related |
|---|
| 17 | 17 | | mental health services, shall conduct a study on the efficacy of |
|---|
| 18 | 18 | | using alternative therapies, including the use of |
|---|
| 19 | 19 | | 3,4-methylenedioxymethamphetamine (MDMA), psilocybin, and |
|---|
| 20 | 20 | | ketamine, in the treatment of veterans and other identified |
|---|
| 21 | 21 | | individuals who suffer from post-traumatic stress disorder. |
|---|
| 22 | 22 | | (c) In conducting the study described by Subsection (b) of |
|---|
| 23 | 23 | | this section, the commission in collaboration with the Baylor |
|---|
| 24 | 24 | | College of Medicine shall: |
|---|
| 25 | 25 | | (1) perform a clinical trial on the therapeutic |
|---|
| 26 | 26 | | efficacy of using psilocybin in the treatment of |
|---|
| 27 | 27 | | treatment-resistant post-traumatic stress disorder in veterans and |
|---|
| 28 | 28 | | other identified individuals; [and] |
|---|
| 29 | 29 | | (2) prescribe standardized protocols for each |
|---|
| 30 | 30 | | researcher or research organization participating in the study; and |
|---|
| 31 | 31 | | (3) review current literature regarding: |
|---|
| 32 | 32 | | (A) the safety and efficacy of |
|---|
| 33 | 33 | | 3,4-methylenedioxymethamphetamine (MDMA), psilocybin, and |
|---|
| 34 | 34 | | ketamine in the treatment of post-traumatic stress disorder; and |
|---|
| 35 | 35 | | (B) the access veterans and other identified |
|---|
| 36 | 36 | | individuals have to 3,4-methylenedioxymethamphetamine (MDMA), |
|---|
| 37 | 37 | | psilocybin, and ketamine for treatment of post-traumatic stress |
|---|
| 38 | 38 | | disorder in the United States. |
|---|
| 39 | 39 | | (d) The commission shall prepare and submit to the governor, |
|---|
| 40 | 40 | | the lieutenant governor, the speaker of the house of |
|---|
| 41 | 41 | | representatives, and each member of the legislature: |
|---|
| 42 | 42 | | (1) quarterly reports on the progress of the study |
|---|
| 43 | 43 | | conducted under this section; and |
|---|
| 44 | 44 | | (2) not later than December 1, 2026 [2024], a written |
|---|
| 45 | 45 | | report containing the results of the study conducted under this |
|---|
| 46 | 46 | | section and any recommendations for legislative or other action. |
|---|
| 47 | 47 | | (f) This Act expires September 1, 2027 [2025]. |
|---|
| 48 | 48 | | SECTION 2. This Act takes effect immediately if it receives |
|---|
| 49 | 49 | | a vote of two-thirds of all the members elected to each house, as |
|---|
| 50 | 50 | | provided by Section 39, Article III, Texas Constitution. If this |
|---|
| 51 | 51 | | Act does not receive the vote necessary for immediate effect, this |
|---|
| 52 | 52 | | Act takes effect September 1, 2023. |
|---|